To meet its vast responsibilities for more than $2.5 trillion in products, the FDA should operate from a structure that best accommodates rigorous, science-based decisionmaking. This White Paper documents the growing demands on the agency and current barriers to regulatory efficiency, and provides supporting evidence for the Commissioners’ consensus recommendation on a two-step pathway to independence.